New Zealand Black (NZB) mice develop after 16 weeks of age an autoimmune and lymphoproliferative disease which is a model for systemic lupus erythematosus and lymphoid malignancy in humans. At this age, the mice manifest a progressive decline in T lymphocyte (thymus-derived lymphocyte) functions and serum thymosin levels. Thymocytes from 8-week old NZB mice exhibit an abnormal DNA synthetic response when transplanted into lethally irradiated C57B1/6 recipients. DNA synthesis (measured as the incorporation of radioactively labeled 5-iodo-2'-deoxyuridine) is delayed in onset and still increasing 6 days after cell transfer. By contrast, 2-week old NZB thymocytes show a normal response which is rapid in onset and completed by day 6. NZB mice were injected with thymosin fraction 5 or with bovine serum albumin starting at 2 weeks of age. Thymocytes from 8-week old thymosin-treated mice showed a normal DNA synthetic response, whereas the albumin-treated controls showed the abnormal response expected at this age. The ability of thymosin to correct the DNA synthetic response was related to dose and duration of treatment. These results suggest that thymosin can induce a more normal state of thymocyte differentiation in NZB mice. If abnormal thymocyte differentiation is related to the subsequent emergence of autoimmunity and lymphoid malignancy, then continuous treatment with thymosin may have therapeutic potential. These experiments suggest that an endocrine disturbance may contribute to autoimmune and lymphoproliferative disease in NZB mice and possibly in humans.
The New Zealand Black (NZB) and related hybrid mice are a useful model for the study of autoimmune and lymphoproliferative disease in man. These mice spontaneously develop findings characteristic of three human disorders, systemic lupus erythematosus, Sjogren's syndrome, and Waldenstrom's macroglobulinemia (1) (2) (3) (4) . These alterations appear after 16 weeks of age and include Coomb's positive hemolytic anemia, antibodies to nucleic acids, immune complex glomerulonephritis and monoclonal macroglobulinemia. Genetic, immunologic, and virologic factors have been implicated in the pathogenesis of their disease (3, 5) .
NZB mice show a progressive loss of T-cell (thymusderived lymphocytes) functions during their lifespan (5) . Even prior to the onset of autoimmunity, their T-cells are resistant to the development of immunologic tolerance (6) (7) (8) . Later in life, the mice have marked deficiencies of various Tcell effector functions such as reactivity to mitogens (9, 10) and ability to induce graft-versus-host disease (11, 12) . At this stage, there is also a deficiency of long-lived recirculating T-cells (13, 14) . Dauphinee and Talal (15) (17) and further purified in 1972 (18) . The 1972 isolation procedure has recently been modified to increase the availability of thymosin for biological and chemical studies (19) . In the present report, thymosin fraction 5 (18) was used. Bach et al. (20) recently demonstrated the presence of thymosin-like material in normal mouse serum and its absence in the serum of congenitally thymus-deficient ("nude") mice. This thymosin-like activity in the serum declines with age in normal mice; the decline occurs prematurely in the serum of NZB and NZB/NZW F1 hybrid mice. By two months of age, at a time when abnormal thymocyte proliferation (15) and T-cell resistance to tolerance (6, 8) are already present, serum thymic activity is insignificant in NZB mice (20 The purification procedure through fraction 5 is as follows.
Thymus tissue is homogenized in 3 volumes of 0.9% NaCl with 0.5% (vol/vol) octyl alcohol added to minimize foaming. The homogenate is centrifuged at 14,000 X 9. Three liter portions of the supernatant are heated with stirring in a boiling water bath. When the temperature reaches 800, the sample is rapidly cooled in an ice water bath. The heat-coagulated Cytotoxicity Assay. In vitro cytotoxic activity of sensitized lymphocytes was determined according to the method of Brunner (22) with slight modifications (15) . Cytotoxicity was measured against 5'Cr-labeled EL-4 lymphoma target cells. Specific cytotoxicity was determined by measuring the release of 51Cr into the medium compared to maximal release (water lysis) using the following expression: (15) and with other normal control strains (21) . By contrast, the cells from 8-week old NZB mice show almost no response on day 4, a slight response on day 5 and a peak response on day 6. This is defined as an abnormal response.
The proliferation of lymph node-seeking thymocytes from NZB mice 2-and 8-weeks of age is also shown in Fig. 1 . The kinetics of response were similar to those seen with the spleenseeking population. The cells from the older animals again showed a delayed onset and no return to baseline.
The results with thymosin-treated NZB mice are shown in Table 1 and Figs. 2, 3 and 4. All mice were studied at 8 weeks.
In group A, thymosin treatment was started at 14 days of age and maintained for a total dose of 0.9 mg given over 6 weeks.
Age and sex-matched control NZB mice were untreated. At 8 weeks of age, both thymosin-treated and untreated mice were sacrificed, and thymocytes injected into irradiated C57Bl/6 recipients. As shown in Fig. 2 cytes from NZB mice 2 weeks of age, whereas the untreated mice had the abnormal response expected at 8 weeks of age.
In groups B and C (Table 1 and Fig. 3 ), treatment was started at 21 and 28 days for a total dose of 0.7 and 0.3 mg, respectively. As a control, age and sex-matched mice received the same quantity of bovine serum albumin (BSA) injected in an identical schedule. Mice receiving thymosin showed a DNA proliferative response characteristic of 2-week old NZB thymocytes, whereas mice receiving BSA showed the customary delayed onset and abnormal response (Fig. 3) .
In groups D and E (Table 1 and Fig. 4 ) treatment started at 35 days of age. Group D (receiving 0.3 mg of thymosin) behaved like untreated mice and showed an abnormal response. By contrast, group E (receiving 3.0 mg of thymosin) showed maintenance of the normal young response pattern. Group F, starting thymosin at 49 days and receiving only 0.3 mg of thymosin, showed no effect of treatment. Effector cell activity was assayed in this experiment; there was no difference in results between thymosin-treated and BSAtreated mice (Fig. 4) . DISCUSSION The progressive loss of T-cell functions throughout life is now well documented in NZB mice (3, 5) . Many of the more severe abnormalities occur after the onset of autoimmunity and are probably a consequence rather than cause of the disease. However, two abnormalities of thymocyte function appear before the onset of autoimmunity, i.e., at about 4 weeks of age. These two abnormalities are: (1) a relative resistance to immunologic tolerance (6-8), and (2) an abnormal proliferative response to alloantigens (15) .
The basis for the T-cell abnormalities in NZB mice is unknown. Profitt, Hirsch, and Black (23) have recently shown that thymocytes infected with Moloney leukemia virus become cytotoxic for noninfected syngeneic cells. NZB thymocytes are infected with murine leukemia virus, readily demonstrable by electron microscopy as C-type particles (24, 25) . If such viral infected thymocytes become cytotoxic for other noninfected thymocytes, a progressive loss of T-cell activity might develop.
NZB mice produce, early in life, an autoantibody capable of destroying thymocytes from NZB and other mouse strains (26) . A thymocytotoxic antibody of this type might also contribute to a state of T-cell deficiency.
Structural (27) Substantial evidence now exists for the importance of thymic humoral factors. These factors probably act locally in the thymus and also on T-cells in peripheral lymphoid organs.
The fact that thymocyte function itself is affected in NZB mice suggests a local action of thymosin. An additional peripheral action is a distinct possibility, particularly since thymic activity is present in normal serum (20) . (31) .
A prominent role in this control mechanism probably can be assigned to the thymus. Thymectomy of normal mice leads to the premature development of Coomb's positive and antinuclear factors. Several authors have suggested that the thymus may express this control through a regulatory mechanism dependent upon suppressor factors or suppressor Tcells (5, 32, 33) . This suppression would act to prevent autoantibody production by B-cells and its effectiveness might diminish with age. Our results suggest that suppression of autoimmunity may be dependent upon thymosin and perhaps other thymic humoral factors. Thymosin could act either to induce the appearance of new T-cells with suppressor-like characteristics or to influence aberrant T-cells to revert to more normal modes of function. These results raise the interesting possibility that an endocrine disturbance may underlie many of the immunologic abnormalities associated with autoimmunity and lymphoid malignancy in New Zealand mice and, by analogy, in humans.
